weight regain after stopping glp-1 agonists Ozempic, Wegovy & Mounjaro: What to Know The risks people are not

With more generic pharmaceuticals hitting the market, the glucagon-like peptide 1 (GLP-1) agonists market is expected to develop in the region

Available from: www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss [Last accessed: December 31, 2023]

Open-label studies, case reports, and studies based solely on correlation data were excluded to ensure recommendations were grounded in robust clinical evidence

2000;528(Pt 1):165176

In this regard, it is noteworthy that metformin increases intestinal glucose utilisation [3], which perhaps could be coupled to GLP-1 production

Generic liraglutide if accessible